QQQ   382.39 (+1.18%)
AAPL   149.48 (+0.57%)
MSFT   310.55 (+0.79%)
FB   322.04 (-2.02%)
GOOGL   2,774.75 (+0.94%)
TSLA   1,086.66 (+6.03%)
AMZN   3,411.01 (+2.73%)
NVDA   251.05 (+8.37%)
BABA   171.81 (-2.47%)
NIO   41.78 (+1.24%)
CGC   13.49 (-0.59%)
GE   108.44 (+2.98%)
AMD   126.05 (+3.02%)
MU   69.23 (+0.68%)
T   25.54 (-0.39%)
F   15.97 (-0.19%)
ACB   7.10 (-1.11%)
DIS   172.96 (+0.55%)
PFE   43.27 (+0.28%)
BA   213.41 (+0.25%)
AMC   36.31 (-1.41%)
QQQ   382.39 (+1.18%)
AAPL   149.48 (+0.57%)
MSFT   310.55 (+0.79%)
FB   322.04 (-2.02%)
GOOGL   2,774.75 (+0.94%)
TSLA   1,086.66 (+6.03%)
AMZN   3,411.01 (+2.73%)
NVDA   251.05 (+8.37%)
BABA   171.81 (-2.47%)
NIO   41.78 (+1.24%)
CGC   13.49 (-0.59%)
GE   108.44 (+2.98%)
AMD   126.05 (+3.02%)
MU   69.23 (+0.68%)
T   25.54 (-0.39%)
F   15.97 (-0.19%)
ACB   7.10 (-1.11%)
DIS   172.96 (+0.55%)
PFE   43.27 (+0.28%)
BA   213.41 (+0.25%)
AMC   36.31 (-1.41%)
QQQ   382.39 (+1.18%)
AAPL   149.48 (+0.57%)
MSFT   310.55 (+0.79%)
FB   322.04 (-2.02%)
GOOGL   2,774.75 (+0.94%)
TSLA   1,086.66 (+6.03%)
AMZN   3,411.01 (+2.73%)
NVDA   251.05 (+8.37%)
BABA   171.81 (-2.47%)
NIO   41.78 (+1.24%)
CGC   13.49 (-0.59%)
GE   108.44 (+2.98%)
AMD   126.05 (+3.02%)
MU   69.23 (+0.68%)
T   25.54 (-0.39%)
F   15.97 (-0.19%)
ACB   7.10 (-1.11%)
DIS   172.96 (+0.55%)
PFE   43.27 (+0.28%)
BA   213.41 (+0.25%)
AMC   36.31 (-1.41%)
QQQ   382.39 (+1.18%)
AAPL   149.48 (+0.57%)
MSFT   310.55 (+0.79%)
FB   322.04 (-2.02%)
GOOGL   2,774.75 (+0.94%)
TSLA   1,086.66 (+6.03%)
AMZN   3,411.01 (+2.73%)
NVDA   251.05 (+8.37%)
BABA   171.81 (-2.47%)
NIO   41.78 (+1.24%)
CGC   13.49 (-0.59%)
GE   108.44 (+2.98%)
AMD   126.05 (+3.02%)
MU   69.23 (+0.68%)
T   25.54 (-0.39%)
F   15.97 (-0.19%)
ACB   7.10 (-1.11%)
DIS   172.96 (+0.55%)
PFE   43.27 (+0.28%)
BA   213.41 (+0.25%)
AMC   36.31 (-1.41%)
ASX:CDY

Cellmid Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Receive CDY News and Ratings via Email

Sign-up to receive the latest news and ratings for Cellmid and its competitors with MarketBeat's FREE daily newsletter.


About Cellmid

Cellmid Limited, a life sciences company, researches, develops, and commercializes diagnostic and therapeutic products for cancer and various chronic inflammatory conditions in Australia, the United States, and Japan. The company offers midkine, a driver and modulator of inflammatory diseases, including chronic inflammatory diseases and cancer; and focuses on blocking midkine, a protein for autoimmune disorders, chronic inflammation, osteoporosis, cardiovascular diseases, cancer, and neurodegenerative diseases. It also develops and sells over-the-counter products; and a range of FGF5 inhibitor hair growth products under the evolis, evolis Professional, Lexilis Hybrid, Jo-Ju RED, and Lexilis BLACK brands. In addition, the company sells SARS-CoV-2 antibody kits and PCR tests. It markets its products through retailers and wholesalers, as well as through a direct-to-consumer e-commerce platform. Cellmid Limited was incorporated in 2004 and is based in Sydney, Australia.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
$5.82 million
Book Value
A$0.06 per share

Profitability

Debt

Price-To-Earnings

Miscellaneous

Next Earnings Date
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.21 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Cellmid (ASX:CDY) Frequently Asked Questions

What stocks does MarketBeat like better than Cellmid?

Wall Street analysts have given Cellmid a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cellmid wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Cellmid's earnings last quarter?

Cellmid Limited (ASX:CDY) posted its quarterly earnings results on Thursday, February, 21st. The company reported ($0.05) earnings per share for the quarter.
View Cellmid's earnings history
.

Who are Cellmid's key executives?

Cellmid's management team includes the following people:
  • Ms. Maria Halasz, CEO, MD & Exec. Director
  • Mr. Koichiro Koike, Managing Director of Advangen Inc (Age 64, Pay $303.67k)
  • Mr. Matthew Dudek, Group Financial Controller
  • Mr. Dominic Burg, Chief Operating Officer
  • Dr. Graham Robertson, Head of R&D
  • Ms. Trish Frelan, Global Head of Marketing Advangen Pty Ltd
  • Mr. Lee Tamplin B.A., Company Sec.

What other stocks do shareholders of Cellmid own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellmid investors own include Westgold Resources (WGX) and Credit Intelligence (CI1).

What is Cellmid's stock symbol?

Cellmid trades on the ASX under the ticker symbol "CDY."

How much money does Cellmid make?

Cellmid has a market capitalization of $0.00 and generates $5.82 million in revenue each year.

What is Cellmid's official website?

The official website for Cellmid is www.cellmid.com.au.

How can I contact Cellmid?

The company can be reached via phone at 61 2 9221 6830.


This page was last updated on 10/26/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.